Earlier in October, the government allowed Serum Institute of India to export one million doses of Covisheild each to Nepal, Myanmar, and Bangladesh under the ‘Vaccine Friendship’ program. Under the Global Immunization Program, the export of 5 million doses of the anti-Covid-19 vaccine Covisheild has been allowed to Nepal, Tajikistan, and Mozambique. Official sources gave this information on Sunday. He said that apart from these three countries, SII will also export Covishield vaccines to Bangladesh under the COVAX initiative. SII will start exporting the Covid vaccine under the COVAX program from 23 November and Nepal will get the first consignment of Covishield on 24 November.
Earlier in October, the government had sent SII to Nepal, Myanmar, and Bangladesh each under the ‘Vaccine Friendship’ program. Prakash Kumar Singh, Director of Government and Regulatory Affairs at Serum Institute of India, in a recent letter to the Union Health Ministry, informed that the company has prepared a stock of 24,89,15,000 doses of Covishield and the stock is available on a day-to-day basis is increasing. Simultaneously, SII had requested the Union Health Ministry to allow the export of the company’s Covovax vaccine.
Poland accepts Covishield and exempts people immunized with it from quarantine
Apart from this, approval was also sought from the ‘Central Drugs Standard Control Organization‘ (CDSCO) in this regard. The company had said that if the Covovax vaccine does not get approval for export, then it may suffer. SII has said in its application that without approval, one crore doses of the Covovax vaccine will be wasted by December 2021. At the same time, Serum had also sought approval for the emergency use of the Covovax vaccine for vaccination in India. However, no decision has been taken by CDSCO on this matter.
